ABSTRACT
Aim: To develop a propranolol HCL-loaded liposomal nasal formulation for migraine prophylaxis. Materials & methods: Formulated the liposomes through thin layer hydration method and optimized via design of experiments (DOE). The prepared liposomes were characterized for particle size, zeta potential, PDI, drug entrapment and drug loading. Assessed for in vitro release kinetics, ex vivo permeability, histopathology and stability. Results: Optimized liposomes: 135.52 ± 5.87 nm, -19.9 ± 0.075 mV, 95.41 ± 0.05% entrapment, 43.37 ± 0.02% loading. Showed immediate (30.07 ± 2.09%) and sustained release (95.69 ± 4.58%) over 10 h. Enhanced permeation compared with controls; well-tolerated histopathologically. Conclusion: Liposomal formulation offers promise for intranasal propranolol HCL delivery in migraine prophylaxis, with stability under refrigeration.
Migraines (a type of long-lasting headache) can be helped by a medicine called propranolol HCL. In this study, scientists developed tiny bubbles, called liposomes, which contained propranolol HCL. The liposomes are designed to be inhaled via the nose, where the medicine is released slowly from the liposomes to treat the migraine. In this study, the researchers made the propranolol HCL-containing liposomes and analyzed them in the lab. They found that the liposomes were safe, and can be kept in a cool place for a long time. So, may be able to help treat migraines.
